Alder BioPharmaceuticals To Present At Two Upcoming November Conferences

BOTHELL, Wash., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast a business overview and update by members of the management team at each of the following upcoming healthcare conferences:
  • 25th Annual Credit Suisse Healthcare Conference at 11:30 a.m. MT on Tuesday, November 8, 2016 in Scottsdale, AZ. 
  • Piper Jaffray 28th Annual Healthcare Conference at 11:30 a.m. ET on Wednesday, November 30, 2016 in New York, NY.

A live audio webcast of each event can be accessed on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for 30 days after the live event concludes.

About Alder BioPharmaceuticals, Inc.Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, ALD403, is being evaluated for migraine prevention. ALD403 is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Media Contacts:David Schull or Todd Davenport, Ph.D.Russo Partners, LLC(212) 845-4271(212) 845-4235david.schull@russopartnersllc.comtodd.davenport@russopartnersllc.comInvestor Relations Contact:David WalseyAlder Biopharmaceuticals(425) 408-8032ir@alderbio.com

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Market Signals Change of Direction: Cramer's 'Mad Money' Recap (Monday 9/18/17)

U.S. Concrete, Alder Biopharmaceuticals: 'Mad Money' Lightning Round

Biotech Movers: Impax Shares Jump on FDA Approval for Generic Version of Concerta

Alder BioPharmaceuticals: Cramer's Top Takeaways